Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04162769 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis
A Phase 2 study of Atopic Dermatitis, sponsored by Arena Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT04162769 is a Phase 2 study of Atopic Dermatitis that has completed, run by Arena Pharmaceuticals. The registered enrollment target is 140 participants, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT04162769, a Phase 2 study of Atopic Dermatitis, has completed, sponsored by Arena Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to determine whether etrasimod is a safe and effective treatment for moderate-to-severe atopic dermatitis (AD).
Conditions Studied
Interventions
- DRUG Etrasimod 1 mg
- DRUG Etrasimod 2 mg
- DRUG Etrasimod matching placebo
Study Locations (20)
Florida
- Clinical Research of West Florida - Clearwater
- Prohealth Research Center - Doral
- Aby's New Generation Research, Inc. - Hialeah
- Skin Care Research, LLC - Hollywood
- Advanced Research Institute of Miami LLC - Homestead
- Amber Pediatrics Research, LLC - Homestead
- South Miami Medical & Research Group. Inc - Miami
- Amber Pediatrics Research, LLC - Miami
- Skin Research of South Florida - Miami
- Amber Clinical Research, LLC - Miami Shores
- IMA Clinical Research, LLC - St. Petersburg
- Clinical Research of West Florida, Inc. - Tampa
California
- Hope Clinical Research - Canoga Park
- First OC Dermatology - Fountain Valley
- Marvel Research LLC - Huntington Beach
- ADVA Clinical Research, Inc - Inglewood
- Providence Clinical Research - North Hollywood
- TCR Medical Corporation - San Diego
Arizona
- Noble Clinical Research - Tucson
Georgia
- Rophe Adult and Pediatric Medicine/SKYCRNG - Union City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2019-10-04 |
| Est. Completion | 2021-10-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04162769
The ClinicalTrials.gov registry entry for NCT04162769 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 140 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 609-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (77% lower). The listed sponsor is Arena Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Atopic Dermatitis appearing as the primary indexed condition, and to 3 interventions - of which Etrasimod 1 mg is the first listed.
NCT04162769 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT04162769 about?
NCT04162769 is a clinical study titled "A Study to Assess the Safety and Efficacy of Etrasimod in Subjects With Moderate-to-Severe Atopic Dermatitis". The purpose of this study is to determine whether etrasimod is a safe and effective treatment for moderate-to-severe atopic dermatitis (AD).
What is the current status of trial NCT04162769?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 140 participants. The study started on 2019-10-04. Estimated completion is 2021-10-11.
What conditions does trial NCT04162769 study?
This clinical trial studies the following conditions: Atopic Dermatitis.
What interventions are being tested in trial NCT04162769?
The interventions under investigation include: Etrasimod 1 mg (DRUG), Etrasimod 2 mg (DRUG), Etrasimod matching placebo (DRUG).
Who is sponsoring clinical trial NCT04162769?
This trial is sponsored by Arena Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04162769 being conducted?
This trial has 20 study locations across Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.